sexta-feira, 13 de novembro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 12, 2026

Citigroup Q4 Earnings on the Deck: How to Approach the Stock Now?

View original at finance.yahoo.com
Citigroup Q4 Earnings on the Deck: How to Approach the Stock Now? Citigroup Inc. C is slated to report fourth-quarter and full-year 2025 results on Jan…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Retail Services NCL is expected to be 5.75-6.25%

    80% confidence
  • The transaction is expected to result in a pre-tax loss of $1.2 billion in the fourth quarter of 2025

    80% confidence
  • Management expects NII (excluding Markets) to rise 5.5% on a year-over-year basis

    80% confidence
  • Citigroup expects market revenues to be down in the low to mid-single digit in the fourth quarter from a year ago

    80% confidence
  • Its earnings outpaced the Zacks Consensus Estimate in the trailing four quarters, the average surprise being 13.19%

    80% confidence
  • The Zacks Consensus Estimate for fourth-quarter sales is pegged at $20.94 billion, indicating a 6.9% year-over-year increase

    80% confidence
  • Management anticipates expenses to be higher than $53.4 billion, including the impacts of FX translation and excluding the goodwill impairment

    80% confidence
  • The company is seeing continued momentum, particularly in M&A

    80% confidence
  • The efficiency ratio is expected to be slightly less than 64%

    80% confidence
  • Branded Cards net credit loss (NCL) is expected to be 3.50-4%

    80% confidence
  • The consensus estimate for earnings for the to-be-reported quarter has been revised downward to $1.65 over the past seven days, indicating a 23.1% rise from the prior-year quarter's actual

    80% confidence
  • Management expects IB fees to increase in the mid-20s (percentage) year over year in the fourth quarter

    80% confidence
  • Citigroup expects revenues to cross $84 billion compared with the prior mentioned $84.1 billion

    80% confidence

Data points we hold from this source

Citigroup Inc. · forward pe ratio11.92 ratio
Citigroup Inc. · non accrual loans3.7 billion_USD
Citigroup Inc. · principal transactions income2.1 billion_USD
Citigroup Inc. · efficiency ratio64 percent
Citigroup Inc. · revenue20.94 billion_USD
Citigroup Inc. · revenue84 billion_USD
Citigroup Inc. · average interest earning assets2.5 trillion_USD
Citigroup Inc. · commissions and fees2.9 billion_USD
Citigroup Inc. · market revenue4.5 billion_USD
Citigroup Inc. · net interest income14.9 billion_USD
Citigroup Inc. · non interest income5.9 billion_USD
Citigroup Inc. · administration and fiduciary fees1.0 billion_USD
Citigroup Inc. · stock repurchase authorization remaining11.3 billion_USD
Citigroup Inc. · dividend per share0.60 USD
Board of Governors of the Federal Reserve System · fed funds rate3.50-3.75 percent
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Late-2026 Biotech Catalyst Season: FDA Decisions and Pivotal Readouts Converge Across Oncology, Hepatology and Cardiometabolic
Mid-November 2026 is dense with scheduled biotech catalysts. The ivonescimab BLA PDUFA date is 2026-11-14, the lorundrostat PDUFA date is 2026-12-22, and Phase 3 ECLIPSE hepatitis delta data are due in Q1 2027. Alongside these, siRNA and antibody programs (plozasiran, elebsiran/tobevibart, ianalumab, nipocalimab) reported or presented data at AHA, AASLD, ACR and ASH, while Oryzon advanced iadademstat in AML with Spanish trial authorizations and a planned ALICE-3 Phase III. Late-stage data and regulatory milestones are driving the sentiment. A planned delisting (EGM 2026-11-19, application 2027-01-25) is a separate corporate-structure event with no clear link to the rest.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,995
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,995 factos verificados com a fonte5,577 documentos-fonte arquivados
Consulte estes dados → isubstrate.com
Citigroup Q4 Earnings on the Deck: How to Approach the Stock Now? — Source | Via News | pt.VIA.NEWS